Cale D Fahrenholtz

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 6

Top Venues

Pharmaceutics

Journal of personalized medicine

International journal of nanomedicine

Science translational medicine

High Point University Fred Wilson School of Pharmacy

This page only lists publications with an associated author ORCID identifier.

Affiliation History

High Point University Fred Wilson School of Pharmacy Jul 01 2019

United States

Assistant Professor :: Basic Pharmaceutical Sciences

Wake Forest School of Medicine Feb 01 2014 - May 12 2019

United States

Research Associate :: Cancer Biology

Publications

Bashnona Attiah, Garrett Alewine, Mary-Kate Easter, Robert A Coover, Cale D Fahrenholtz
Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibroma Cells at Doses That Do Not Affect Patient-Matched Schwann Cells. Pharmaceutics 16 (3) (2024)
Bashnona Attiah, Garrett Alewine, Mary-Kate Easter, Robert A Coover, Cale D Fahrenholtz
Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibroma Cells at Doses That Do Not Affect Patient-Matched Schwann Cells. Pharmaceutics 16 (3) (2024)
Bashnona Attiah, Garrett Alewine, Mary-Kate Easter, Robert A Coover, Cale D Fahrenholtz
Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibroma Cells at Doses That Do Not Affect Patient-Matched Schwann Cells. Pharmaceutics 16 (3) (2024)
Garrett Alewine, Jerrica Knight, Adithya Ghantae, Christina Mamrega, Bashnona Attiah, Robert A Coover, Cale D Fahrenholtz
Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors in a Neurofibromin-Dependent Manner. Journal of personalized medicine 12 (7) (2022)
James Sears, Jessica Swanner, Cale D Fahrenholtz, Christina Snyder, Monica Rohde, Nicole Levi-Polyachenko, Ravi Singh
Combined Photothermal and Ionizing Radiation Sensitization of Triple-Negative Breast Cancer Using Triangular Silver Nanoparticles. International journal of nanomedicine 16 (2021)
Ning Zhao, Stephanie O Peacock, Chen Hao Lo, Laine M Heidman, Meghan A Rice, Cale D Fahrenholtz, Ann M Greene, Fiorella Magani, Valeria A Copello, Maria Julia Martinez, Yushan Zhang, Yehia Daaka, Conor C Lynch, Kerry L Burnstein
Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. Science translational medicine 11 (498) (2020)

Cale D Fahrenholtz.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Cale D Fahrenholtz